Stifel Financial Corp Has $9.04 Million Stock Holdings in Mylan NV (NASDAQ:MYL)

Stifel Financial Corp decreased its position in Mylan NV (NASDAQ:MYL) by 28.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 456,131 shares of the company’s stock after selling 181,260 shares during the quarter. Stifel Financial Corp owned approximately 0.09% of Mylan worth $9,035,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of MYL. Vanguard Group Inc. lifted its stake in shares of Mylan by 19.2% in the second quarter. Vanguard Group Inc. now owns 56,048,375 shares of the company’s stock valued at $1,067,160,000 after buying an additional 9,026,215 shares during the period. Banco Santander S.A. bought a new position in Mylan in the 3rd quarter valued at $55,384,000. Nuveen Asset Management LLC increased its stake in shares of Mylan by 824.3% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,681,501 shares of the company’s stock valued at $31,898,000 after buying an additional 1,499,579 shares during the period. Point72 Asset Management L.P. raised its position in shares of Mylan by 312.6% during the second quarter. Point72 Asset Management L.P. now owns 1,769,543 shares of the company’s stock worth $33,692,000 after acquiring an additional 1,340,643 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Mylan by 11.0% during the second quarter. AQR Capital Management LLC now owns 11,247,227 shares of the company’s stock worth $213,473,000 after acquiring an additional 1,111,009 shares during the last quarter. Institutional investors and hedge funds own 86.54% of the company’s stock.

Several equities analysts recently issued reports on the company. SunTrust Banks raised their price target on Mylan from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, September 12th. ValuEngine upgraded Mylan from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Morgan Stanley cut Mylan from an “overweight” rating to an “equal” rating and decreased their target price for the company from $25.00 to $18.00 in a research note on Thursday, November 7th. BidaskClub upgraded Mylan from a “sell” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Evercore ISI reaffirmed a “buy” rating on shares of Mylan in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. Mylan presently has a consensus rating of “Buy” and an average price target of $27.97.

MYL stock opened at $18.53 on Wednesday. The firm has a market cap of $9.56 billion, a price-to-earnings ratio of 4.05, a PEG ratio of 1.01 and a beta of 1.72. The company has a quick ratio of 0.84, a current ratio of 1.43 and a debt-to-equity ratio of 1.17. Mylan NV has a 12-month low of $16.63 and a 12-month high of $34.35. The company’s fifty day simple moving average is $18.29 and its 200 day simple moving average is $18.88.

Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.03. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The firm had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.01 billion. During the same period last year, the business posted $1.25 EPS. The business’s revenue was up 3.5% compared to the same quarter last year. Research analysts expect that Mylan NV will post 4.31 earnings per share for the current year.

In related news, insider Goulds Bruce 8,000,000 shares of Mylan stock in a transaction dated Friday, November 8th. Corporate insiders own 0.82% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

See Also: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.